Alternatives to Ogsiveo If You Can't Fill Your Prescription

Ogsiveo (nirogacestat) is the first and only FDA-approved systemic treatment for adults with progressing desmoid tumors. But not every patient can access it right away — prior authorization delays, insurance denials, financial barriers, and specialty pharmacy logistics can all create gaps in therapy. In some cases, patients may not tolerate Ogsiveo or may be looking for additional treatment options alongside it.

This guide outlines the most commonly used alternatives and adjunct treatments that oncologists consider when Ogsiveo isn't immediately available or tolerated. Always discuss any treatment changes with your oncologist before making adjustments — desmoid tumor management is highly individualized.

Why Alternatives Matter for Desmoid Tumor Patients

Before Ogsiveo's approval in November 2023, there was no FDA-approved systemic therapy specifically for desmoid tumors. Oncologists relied on a range of off-label treatments that showed varying degrees of efficacy in clinical studies and real-world practice. These treatments continue to be relevant as alternatives, bridge therapies, or options for patients who cannot access or tolerate nirogacestat.

Tyrosine Kinase Inhibitors (TKIs)

TKIs are among the most frequently used alternatives to Ogsiveo for desmoid tumors. Several agents have been studied in clinical trials or used in practice:

Sorafenib (Nexavar): A multi-targeted TKI that has been evaluated in clinical trials for desmoid tumors and shown some evidence of disease control. It blocks VEGFR, PDGFR, and Raf kinase pathways. Common side effects include hand-foot skin reaction, fatigue, and diarrhea.

Imatinib (Gleevec): A targeted therapy used off-label in desmoid tumors, particularly in patients with PDGFR mutations. Response rates have been modest in published studies, but some patients achieve disease stabilization.

Pazopanib (Votrient): Another multi-kinase inhibitor used in soft tissue sarcomas. It is used off-label in desmoid tumors when other options are unavailable or have failed.

Hormonal Therapy

Some desmoid tumors, particularly in young women, are hormonally driven. Anti-estrogen agents have been used in this context:

Tamoxifen: Often combined with a non-steroidal anti-inflammatory drug (NSAID) like sulindac. Some guidelines have recommended this combination as a first-line option for lower-risk desmoid tumors, particularly in patients who want to avoid more aggressive therapies.

Toremifene: Another anti-estrogen agent sometimes considered in the same context as tamoxifen.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)

Celecoxib (Celebrex) and sulindac have been used in desmoid tumor management, often in combination with hormonal agents. These are generally considered low-intensity options and may be appropriate for patients with slowly growing, lower-risk tumors who do not require more aggressive systemic therapy.

Cytotoxic Chemotherapy

For patients with rapidly progressing desmoid tumors who need a fast response — or who have exhausted other options — conventional chemotherapy remains an option:

Doxorubicin-based regimens: Used when rapid disease control is needed. Carries significant cardiac and other systemic toxicities.

Carboplatin + vinca alkaloids: Sometimes used in pediatric patients or in settings where other options are not available.

Active Surveillance: Sometimes 'Watchful Waiting' Is the Plan

Not all desmoid tumors require immediate systemic treatment. Some desmoid tumors spontaneously stabilize or even regress without any therapy. For patients with asymptomatic, slowly growing tumors, active surveillance (also called watchful waiting) — with regular imaging — may be appropriate. This avoids the side effects and cost of systemic therapy until there is evidence of significant progression or symptoms.

How to Have the Conversation With Your Oncologist

If you're unable to access Ogsiveo, bring these questions to your next appointment:

What is the urgency of starting systemic therapy — is watchful waiting an option while we work on access?

Would a TKI like sorafenib or imatinib be appropriate in the interim?

Are there any clinical trials I may be eligible for?

Has the SpringWorks Patient Assistance Program been explored for my case?

If access is the primary barrier, make sure you've explored all the tools at your disposal. Check out our guides on how to find Ogsiveo in stock and how to save money on Ogsiveo before switching to an alternative.